|Shareholder/Beneficial Owner||Shares||% ISC|
|Lombard Odier Investment Managers||81,452,878||10.12|
|T Rowe Price Global Investments||79,122,144||9.83|
|Canaccord Genuity Wealth Management||71,716,260||8.91|
|Hargreaves Lansdown, stockbrokers||50,306,277||6.25|
|Dr Andrew Nelson*||40,567,234||5.04|
as at 31 January 2023
Quoted: AIM (London Stock Exchange)
Other Exchanges / Trading Platforms: The Company is not listed on any other exchanges or trading platforms.
Number of securities in issue: 804,885,350 Ordinary shares.
Shares not in public hands: Insofar as the Company is aware, the percentage of securities that is not in public hands is 33.8%, these being held by directors, their families and significant shareholders.
Own shares held in treasury: The Company holds 4,115 Ordinary Shares in treasury.
Details on any restrictions on the transfer of securities: There are no restrictions on the transfer of securities.
Applicable code(s): The Company is subject to the UK City Code on Takeovers and Mergers. The Code is administered by The Panel and Takeovers in Mergers.
* Per the Company’s RNS announcement of 11 May 2020, 12,121,711 Ordinary Shares of Dr Nelson’s total beneficial interest are subject to a Sale and Repurchase Agreement with Equities First Holdings.